Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Generalized Pustular Psoriasis: early-phase trial registry
1 of 4 indexed Generalized Pustular Psoriasis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Generalized Pustular Psoriasis: 4 US clinical trials tracked, 1 recruiting.
Generalized Pustular Psoriasis is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Boehringer Ingelheim, running 3 of these trials.
Enrollment posture brief
Registry condition generalized-pustular-psoriasis
OPEN 1 | RECR 25% | LATE 1 | EARLY 2 | RANK #4115 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Generalized Pustular Psoriasis lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Generalized Pustular Psoriasis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Generalized Pustular Psoriasis is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry
CorEvitas
NCT06100991
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
Boehringer Ingelheim
NCT03886246
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
Boehringer Ingelheim
NCT06013969
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
Boehringer Ingelheim
NCT04399837
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Generalized Pustular Psoriasis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Generalized Pustular Psoriasis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Generalized Pustular Psoriasis page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Generalized Pustular Psoriasis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Boehringer Ingelheim sponsors the most Generalized Pustular Psoriasis trials on record, review their full trial history before evaluating a specific study. See Boehringer Ingelheim's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Generalized Pustular Psoriasis condition card totals 4 registered trials; most-linked intervention Spesolimab; top US site state Michigan. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.